Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome

Drugs

Volumn 68, Issue 8, 2008, Pages 1049-1066

  Galie, Nazzareno ^a   Manes, Alessandra ^a   Palazzini, Massimiliano ^a   Negro, Luca ^a   Marinelli, Alessandro ^a   Gambetti, Simona ^a   Mariucci, Elisabetta ^a   Donti, Andrea ^a   Branzi, Angelo ^a   Picchio, Fernando M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Beraprost, therapeutic use; Bosentan, therapeutic use; Congenital heart disorders; Epoprostenol, therapeutic use; Pulmonary hypertension, treatment; Sildenafil, therapeutic use; Sitaxentan, therapeutic use; Tadalafil, therapeutic use

Indexed keywords

ANTIARRHYTHMIC AGENT; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; WARFARIN;

ALTITUDE; ANTICOAGULATION; ARTERIAL OXYGEN SATURATION; ARTERY THROMBOSIS; AVIATION; BIRTH CONTROL; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOSIS; EISENMENGER COMPLEX; ELECTIVE SURGERY; ENDOTHELIAL DYSFUNCTION; HEART ARRHYTHMIA; HEART LUNG TRANSPLANTATION; HEART RIGHT VENTRICLE FAILURE; HEART SEPTUM DEFECT; HEMATOCRIT; HEMOPTYSIS; HUMAN; HYPERVISCOSITY SYNDROME; INFECTION PREVENTION; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MULTICENTER STUDY; PHLEBOTOMY; PHYSICAL ACTIVITY; PREGNANCY; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYNCOPE; SYSTEMIC PULMONARY SHUNT; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; EISENMENGER COMPLEX; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PROGNOSIS; PROSTAGLANDINS; PULMONARY CIRCULATION; RECEPTORS, ENDOTHELIN;

SYNCOPE;

EID: 43749107536     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868080-00004     Document Type: Review

References (111)

1. Galie N, Rubin L. Pulmonary arterial hypertension: epidemiology, pathobiology, assessment and therapy. J Am Coll Cardiol 2004; 43: S1-90
2. Eisenmenger V. Die angeboren Defects des Kammerscheidewand des Herzen. Z Klin Med 1897; 32: 1-28
3. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults: second of two parts [published erratum appears in N Engl J Med 2000 Mar 30; 342 (13): 988]. N Engl J Med 2000; 342: 334-342
4. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period: The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26: 2325-33
5. Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120: 198-204
6. Engelfriet PM, Duffels MGJ, Moller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007; 93: 682-7
7. Simonneau G, Galie N, Rubin L, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: S5-12
8. Lee SD, Shroyer KR, Markham NE, et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101: 927-34
9. Galie N. Classification of patients with congenital systemic-to-pulmonary shunts associated with pulmonary hypertension: current status and future directions. In: Beghetti M, Barst R, Naeije R, et al., editors. Pulmonary arterial hypertension related to congenital heart disease. Munchen: Elsevier, 2006: 11-7
10. Gatzoulis MA, Barst RJ, Fineman J, et al. Eisenmenger's syndrome and pulmonary arterial hypertension in adults with congenital heart disease. Curr Med Res Opin 2007; 23 Suppl. 2: S19-25
11. van Albada ME, Berger RMF. Pulmonary hypertension in the setting of the congenital cardiac disease: the need for refinement of the Evian-Venice classification. Cardiol Young 2008; 18: 10-17
12. Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart: cleaning up a dog's dinner. Cardiol Young 2008; 18: 22-25
13. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger's syndrome: factors relating to deterioration and death. Eur Heart J 1998; 19: 1845-55
14. Besterman E. Atrial septal defects with pulmonary hypertension. Br Heart J 1961; 23: 587-98
15. Hoffman JE, Rudolph AM. The natural history of ventricular septal defects in infancy. Am J Cardiol 1985; 16: 634-53
16. Steele P, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive disease: long-term follow-up and prediction of outcome after surgical correction. Circulation 1987; 76: 1037-42
17. Vogel M, Berger F, Kramer A, et al. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 1999; 82: 30-3
18. Kidd L, Driscoll D, Gersony W, et al. Second natural history study of congenital heart defects: results of treatment of patients with ventricular septal defects. Circulation 1993; 87: 138-51
19. Neumayer U, Stone S, Somerville J. Small ventricular septal defects in adults. Eur Heart J 1988; 19: 1573-82
20. Task FM, Galie N, Torbicki A, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-78
21. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30
22. Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-9
23. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. 1): S25-32
24. Humbert M, Morrell N, Archer S, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. 1): S13-24
25. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-65
26. Cowan KN, Heilbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000; 6: 698-702
27. Du L, Sullivan CC, Chu D, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348: 500-9
28. Vongpatanasin W, Brickner ME, Hillis LD, et al. The Eisenmenger's syndrome in adults. Ann Intern Med 1998; 128: 745-55
29. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005; 112: 828-35
30. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115: 1039-50
31. Broberg C, Ujita M, Babu-Narayan S, et al. Massive pulmonary artery thrombosis with haemoptysis in adults with Eisenmenger's syndrome: a clinical dilemma. Heart 2004; 90: e63
32. Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in eisenmenger's syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007; 50: 634-42
33. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger's syndrome: a combined retrospective and case-control study. Eur Heart J 2006; 27: 1737-42
34. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger's syndrome. J Heart Lung Transplant 1996; 15: 100-5
35. Berman EB, Barst RJ. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis 2002; 45: 129-38
36. Deanfield J, Thaulow E, Warnes C, et al. Management of grown up congenital heart disease. Eur Heart J 2003; 24: 1035-84
37. Galie N, Beghetti M, Gatzoulis MA, et al., for the Bosentan Randomized Trial of Endothelin Antagonist Therapy. Bosentan therapy in patients with eisenmenger's syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54
38. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114: 1482-9
39. Avila WS, Grinberg M, Snitcowsky R, et al. Maternal and fetal outcome in pregnant women with Eisenmenger's syndrome. Eur Heart J 1995; 16: 460-4
40. Uebing A, Steer PJ, Yentis SM, et al. Pregnancy and congenital heart disease. BMJ 2006; 332: 401-6
41. Yentis SM, Steer PJ, Plaat F. Eisenmenger's syndrome in pregnancy: maternal and fetal mortality in the 1990s. Br J Obstet Gynaecol 1998; 105: 921-2
42. Oakley C, Child A, Lung B, et al. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24: 761-81
43. Kiely DG, Charles EA, Webster VJ, et al. Pregnancy and pulmonary hypertension: new approaches to the management of a lifethreatening combination. In: Steer PJ, Gatzoulis MA, Baker P, editors. Heart disease and pregnancy. London: RCOG press, 2006: 211-30
44. Broberg CS, Uebing A, Cuomo L, et al. Adult patients with Eisenmenger's syndrome report flying safely on commercial airlines. Heart 2007 Dec; 93 (12): 1599-603
45. Girgis A, Sanson-Fisher RW. Breaking bad news: consensus guidelines for medical practitioners. J Clin Oncol 1995; 13: 2449-56
46. Stewart M, Davidson K, Meade D, et al. Group support for couples coping with a cardiac condition. J Adv Nurs 2001; 33: 190-9
47. Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006; 48: 356-65
48. Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger's syndrome. Am J Respir Crit Care Med 2001; 164: 1682-7
49. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11
50. Post MC, Janssens S, Van de Werf F, et al. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 2004; 25: 1651-6
51. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990; 112: 485-91
52. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302
53. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 425-34
54. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23
55. Langleben D, Christman BW, Barst RJ, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002; 143: E4
56. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4
57. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903
58. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-502
59. Olschewski H, Simonneau G, Galie N, et al., for the AIR Study Group. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9
60. Barst RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41 (12): 2119-25
61. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-9
62. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-7
63. Sastry BKS, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension-1: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-53
64. Galie N, Ghofrani HA, Torbicki A, et al., and the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57
65. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-56
66. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-63
67. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36
68. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-65
69. Barst R, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Resp Crit Care Med 2004; 169 (4): 441-7
70. Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger's physiology. Am J Cardiol 2003; 91: 632-5
71. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302
72. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival, J Am Coll Cardiol 2002; 40: 780-788
73. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-82
74. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-37
75. Cacoub P, Dorent R, Maistre G, et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger's syndrome. Am J Cardiol 1993; 71: 448-50
76. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-9
77. Christensen DD, McConnell ME, Book WM, et al. Initial experience with bosentan therapy in patients with the Eisenmenger's syndrome. Am J Cardiol 2004; 94: 261-3
78. Gatzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger's physiology. Int J Cardiol 2005; 98: 147-51
79. Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart 2005; 91 (11): 1447-52
80. Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 2005; 150: 716-e7-12
81. Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007; 93: 974-6
82. Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 2007; 93: 350-4
83. Gatzoulis MA, Beghetti M, Galie N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger's syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. Epub 2007. doi:10.1016/j.ijcard. 2007.04.078
84. van Loon RLE, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007; 154: 776-82
85. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999; 274: 13729-32
86. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100 (2): 131-8
87. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238-48
88. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: S68-72
89. Celermajer DS, Cullen S, Deanfild JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993; 87: 440-6
90. Singh T, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: 851-e1-5
91. Lim ZS, Salmon AP, Vettukattil JJ, et al. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Int J Cardiol 2007; 118: 178-82
92. Chau EMC, Fan KYY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger's syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120: 301-5
93. Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol 2007; 120: 306-13
94. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274-80
95. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger's syndrome: a preliminary observational study. Circulation 2006; 114: 1807-10
96. Palazzini M, Manes A, Romanazzi S, et al. Effects of sildenafil treatment in patients with pulmonary hypertension associated with congenital cardiac shunts [abstract]. Eur Heart J 2007; 28: 308
97. Hoeper M, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving non-parenteral prostanoids. Eur Respir J 2003; 22: 339-43
98. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-64
99. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-10
100. Hoeper M, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 4 (28): 691-4
101. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29: 469-75
102. Humbert M, Barst R, Robbins I, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24 (3): 353-9
103. Simonneau G, Rubin L, Galie N, et al. Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2007; 175: A300
104. Therrien J, Warnes C, Daliento L, et al. Canadian Cardiovascular Society Consensus Conference 2001 update: recommendations for the management of adults with congenital heart disease part III. Can. J Cardiol 2001; 17: 1135-58
105. Frost AE, Quinones MA, Zoghbi WA, et al. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005; 24: 501-3
106. Schwerzmann M, Zafar M, McLaughlin PR, et al. Atrial septal defect closure in a patient with 'irreversible' pulmonary hypertensive arteriopathy. Int J Cardiol 2006; 110: 104-7
107. Eicken A, Balling G, Gielden HP et al. Transcatheter closure of a non-restrictive patent ductus arteriosus with an Amplatzer muscular ventricular septal defect occluder. Int J Cardiol 2007; 117: c40-2
108. Dimopoulos K, Peset A, Gatzouulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol. Epub 2008. doi: 10.1016/j.ijcardio.2008.02.004
109. Klepetko W, Mayer E, Sandoval J, et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 73-80S
110. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based guidelines for clinical practice. Chest 2004; 126: 35-62S
111. Galie N, Torbicki A, Barst R, et al. Pocket guidelines on the diagnosis and treatment of pulmonary arterial hypertension. Sophia Antipolis: European Society of Cardiology, 2006